

**Vote-by-mail form**  
for the GENERAL MEETING OF SHAREHOLDERS held on 01/02.07.2024

The undersigned \_\_\_\_\_ [individual shareholder's full name], identified by \_\_\_\_\_ [identity card], series \_\_\_\_\_, number \_\_\_\_\_, issued by \_\_\_\_\_, on \_\_\_\_\_, domiciled in \_\_\_\_\_, National Identification Number \_\_\_\_\_,

or

The undersigned \_\_\_\_\_ [name of the entity/legal person], established in \_\_\_\_\_, registered at the Trade Register Office under no. J \_\_\_\_\_ Unique Registration Code \_\_\_\_\_, legally represented by \_\_\_\_\_ (\*)

shareholder on the reference Date, i.e. **18.06.2024**, of Antibiotice Iasi, a trading company registered at the Trade Register Office under number J22/285/1991, fiscal code 1973096, holding a number of \_\_\_\_\_ shares, representing \_\_\_\_\_% of the total **671,338,040** shares issued by the Company, which grant me \_\_\_\_\_ voting rights in the General Meetings of Shareholders representing \_\_\_\_\_% of the total voting rights,

being aware of the Agenda for the General Meeting of the Shareholders of *Antibiotice Iasi* convened on **01.07.2024**, at 10:00 am, and respectively **02.07.2024**, at 10:00 am, (in the event that the conditions for organizing the General Meetings of Shareholders will not be met on the first above-mentioned date) and being aware of the documentation provided by *Antibiotice* in connection with these agendas,

and in accordance with Article 208 of the ASF Regulation no. 5/2018, I hereby exercise my right to vote by mail, as follows:

No.	Agenda for Ordinary General Meeting of Shareholders	Option		
		for	against	abstention
0	1	2	3	4
1.	Approval of the integral component of the selection plan within the selection procedure triggered by Decision no. 4 of the OGMS on 14.09.2023.			
2.	Approval of the distribution of net profit for 2023, fixing of the gross dividend per share and setting the date of 11.10.2024 as the date for starting the payment;			

3.	Approval of the date of 24.09.2024 as the registration date for identifying the shareholders on whom the effects of the adopted decisions are reflected, in accordance with the provisions of art. 86, para. 1 of Law 24/2017 on issuers of financial instruments and market operations, and setting the date of 23.09.2024 as the ex-date.			
----	---	--	--	--

**I hereby attach:**

- Certified copy of the shareholder’s ID - for individual shareholders (Identity card/passport/residence permit);
- Copy of the registration certificate for the legal persons/entities;
- Certified copy of the ID with respect to authorized agents/ attorneys-in-fact who are individuals (Identity card/passport/residence permit), if applicable;
- Special Power of Attorney for the agent/attorney-in-fact, in original (if applicable).

Contact phone number \_\_\_\_\_

I/The undersigned, am fully and exclusively liable for the stipulations contained therein, in my capacity as shareholder of Antibiotice trading company.

Date \_\_\_\_\_

*Individual shareholder*

\_\_\_\_\_  
 (Full name of the shareholder - in capitals)

\_\_\_\_\_  
 (Shareholder’s signature)

*Corporate shareholder*

\_\_\_\_\_  
 (Name of the shareholder - in capitals)

\_\_\_\_\_  
 (Full name and position of the shareholder’s legal representative - in capitals)

\_\_\_\_\_  
 (Seal and signature of the shareholder’s legal representative)

Contact phone no. \_\_\_\_\_

Note:

(\*) to be completed for entities/corporate shareholders only.

The voting form by mail will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting.

In the event of updating the Vote-by-mail form, please check the requirements in the GM Convening Notice starting with the 16<sup>th</sup> day after the publication of the Convening Notice.

After filling in and signing the Vote by mail, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice Registrar's Office by 29.06.2024, 10:00 am at the latest.